Medication options in the treatment of treatment-resistant depression

Australian and New Zealand Journal of Psychiatry

Volumn 38, Issue 4, 2004, Pages 219-225

  Pridmore, Saxby ^a   Turnier Shea, Yvonne ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Antidepressants; Combined antidepressants; Depression; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CYTOCHROME P450; FLUOXETINE; HISTAMINE RECEPTOR; IMIPRAMINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; REBOXETINE; RISPERIDONE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROID HORMONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ARTICLE; BODY WEIGHT DISORDER; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; LIVER TOXICITY; MAJOR DEPRESSION; MEDICAL LITERATURE; MONOTHERAPY; POLYDIPSIA; POLYURIA; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; RASH; REMISSION; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PSYCHOLOGY; TACHYCARDIA; URINE RETENTION;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; THYROID HORMONES;

EID: 2342653441     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2004.01335.x     Document Type: Article

References (73)

1. Heimann H. Therapy-resistant depression: symptoms and syndromes contributions to symptomatology and syndromes. Pharmakopsychiatrie Neuropsychopharmakologie 1974; 7:199-144.
2. Fagiolini A, Kupfer D. Is treatment-resistant depression a unique subtype of depression? Biological Psychiatry 2003; 53:640-648.
3. Thase M, Rush A. Treatment-resistant depression. In: Bloom F, Kupfer D, eds. Psychopharmacology: the fourth generation of progress. New York: Raven, 1995; 1081-1098.
4. Wilhelm K, Mitchell P, Boyce P et al. Treatment resistant depression in an Australian context I. the utility of the term and approaches to management. Australian and New Zealand Journal of Psychiatry 1994; 28:14-22.
5. Ellis P, Hickie I, Smith D. Summary of guidelines for the treatment of depression. Australasian Psychiatry 2003; 11:34-38.
6. Mitchell P, Malhi G, Redwood B, Ball J. Summary of guidelines for the treatment of bipolar disorder. Australasian Psychiatry 2003; 11:39-53.
7. Mulder R, Joyce P, Lusty S. The relationship of personality disorders to treatment outcome in depressed outpatients. Journal of Clinical Psychiatry 2003; 64:259-264.
8. Krishnan K. Comorbidity and depression treatment. Biological Psychiatry 2003; 53:701-706.
9. Frankle W, Perlis R, Deckersbach T et al. Bipolar depression: relationship between episode length and antidepressant treatment. Psychological Medicine 2002; 32:1417-1423.
10. Akiskal H, Bourgeois M, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders 2000; 59:S5-S30.
11. Thase M, Rush A. When at first you don't succeed: sequential strategies for antidepressant nonresponders. Journal of Clinical Psychiatry 1997; 58(Suppl. 13):23-29.
12. Tohen M, Baker R. Olanzapine and olanzapine plus fluoxetine vs. placebo for bipolar depression [abstract]. Presented at the 155th annual meeting of the American Psychiatric Association, 18-23 May, 2002. Philadelphia: American Psychiatric Association, 2002.
13. Shelton R, Tollefson G, Tohen M et al. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 2001; 158:131-134.
14. Matthews J, Bottonari K, Polania L et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. Journal of Clinical Psychiatry 2002; 63:1167-1170.
15. Keck P, McElroy S. New approaches in managing bipolar depression. Journal of Clinical Psychiatry 2003; 64(Suppl. 1):13-18.
16. Malhi G, Mitchell P, Salim S. Bipolar depression: management options. CNS Drugs 2003; 17:9-25.
17. Kessler R, McGonagle K, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry 1994; 51:8-19.
18. Dunner D. Acute and maintenance treatment of chronic depression. Journal of Clinical Psychiatry 2001; 62(Suppl. 6):10-16.
19. Crown W, Finkelstein S, Berndt E et al. The impact of treatment-resistant depression on health care utilization and costs. Journal of Clinical Psychiatry 2002; 63:963-971.
20. Frank E, Prien R, Jarrett R et al. Conceptualisation and rationale for consensus definitions of terms in major depression. Archives of General Psychiatry 1991; 48:851-855.
21. Manning J. Difficult-to-treat depressions: a primary care perspective. Journal of Clinical Psychiatry 2003; 64(Suppl. 1):24-31.
22. Nierenberg A, Wright E. Evolution of remission as the new standard in the treatment of depression. Journal of Clinical Psychiatry 1999; 60(Suppl. 22):7-11.
23. Rush J, Thase M, Dube S. Research issues in the study of difficult-to-treat depression. Biological Psychiatry 2003; 53:743-753.
24. Thase M, Entsuah A, Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001; 178:234-241.
25. Ferrier I. Treatment of major depression: Is improvement enough? Journal of Clinical Psychiatry 1999; 60(Suppl. 6):10-14.
26. US Department Health Human Services. Clinical Practice Guidelines Number 5: Depression in Primary Care, Vol. 2 Treatment of Major Depression. Rockville, MD: US Department Health Human Services, 1993.
27. Nierenberg A, Amsterdam J. Treatment-resistant depression: definition and treatment approaches. Journal of Clinical Psychiatry 1990; 51(Suppl. 6):39-47.
28. Ellis P, Hickie I, Smith D. RANZCP Clinical Practice Guidelines. Summary of guidelines for the treatment of depression. Australasian Psychiatry 2003; 11:29-33.
29. Beckham E, Leber W. Handbook of depression, 2nd edn. New York: Guilford, 1995.
30. Nelson J. Overcoming treatment resistance in depression. Journal of Clinical Psychiatry 1998; 59(Suppl. 16):13-19.
31. Dinan T. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatrica Scandinavica 1993; 88:300-301.
32. Katona C, Abou-Saleh M, Harrison D. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. British Journal of Psychiatry 1995; 166:80-86.
33. Prange A, Wilson I, Rabon A, Lipton M. Enhancement of imipramine antidepressant activity by thyroid hormone. American Journal of Psychiatry 1969; 126:457-469.
34. Ostroff R, Nelson J. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Journal of Clinical Psychiatry 1999; 60:256-259.
35. Hirose S, Ashby C. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. Journal of Clinical Psychiatry 2002; 63:733-736.
36. Karki S, Masood G. Combination risperidone and SSRI-induced serotonin syndrome. Annals of Pharmacology 2003; 37:388-391.
37. Nelson J. Managing treatment-resistant major depression. Journal of Clinical Psychiatry 2003; 64(Suppl. 1):5-12.
38. Thase M, Rush A, Kornstein S et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry 2002; 59:233-239.
39. Nierenberg A, Papakostas G, Petersen T et al. Nortriptyline for treatment-resistant depression. Journal of Clinical Psychiatry 2003; 64:35-39.
40. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. British Journal of Psychiatry 2001; 178:129-144.
41. Poirer M, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind randomised comparison. British Journal of Psychiatry 1999; 175:12-16.
42. Fava M, Dunner D, Greist J et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment: an open trial. Journal of Clinical Psychiatry 2001; 62:413-420.
43. Stahl M. Essential psychopharmacology. Cambridge: Cambridge University Press, 1996.
44. Crismon M, Trivedi M, Pigott T et al. The Texas Medication Algorithm Project. Report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry 1999; 60:142-156.
45. Bauer M, Whybrow P, Angst J, Versiani M, Moller H-J. World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World Journal of Biological Psychiatry 2002; 3:5-43.
46. Steffens D, McQuoid D, Krishnan K. The Duke somatic treatment algorithm for geriatric depression [STAGED] approach. Psychopharmacological Bulletin 2002; 36:58-68.
47. Adli M, Berghofer A, Linden M et al. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorder: results of a 2-year observational algorithm study. Journal of Clinical Psychiatry 2002; 63:782-790.
48. Hirschfeld R, Montgomery S, Aguglia E et al. Partial and nonresponse to antidepressant therapy: current approaches and treatment options. Journal of Clinical Psychiatry 2002; 63:826-837.
49. Kelsey J. Treatment strategies in achieving remission in major depressive disorder. Acta Psychiatrica Scandinavica Supplement 2002; 415:18-23.
50. Lam R, Wan D, Cohen N, Kennedy S. Combining antidepressants for treatment-resistant depression: a review. Journal of Clinical Psychiatry 2002; 63:685-693.
51. Shioe K, Kanba S. Algorithms for the pharmacotherapy of major depression. Psychiatry and Clinical Neuroscience 1999; 53:S77-S82.
52. Fava M. Augmentation and combination strategies in treatment-resistant depression. Journal of Clinical Psychiatry 2001; 62(Suppl. 18):4-11.
53. Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. Journal of Clinical Psychiatry 1996; 57:257-264.
54. Debonnel G, Gobbi G, Turcotte J. The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double blind controlled study. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology 10-14 December, 2000. San Juan, Puerto Rico: American College of Neuropsychopharmacology, 2000.
55. Carpenter L, Yasmin S, Price L. A double blind, placebo controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry 2002; 51:183-188.
56. Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. Journal of Clinical Psychiatry 1999; 60:260-261.
57. Demers J, Malone M. Serotonin syndrome induced by fluvoxamine and mirtazapine. Annals of Pharmacotherapy 2001; 35:1217-1220.
58. Hawley C, Sivakumaran T, Ochocki M. Co-administration of reboxetine and serotonin selective reuptake inhibitors in treatment-resistant patients with major depression. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology 10-14 December, 2000. San Juan, Puerto Rico: American College of Neuropsychopharmacology, 2000.
59. Dursun S, Devarajan S. The safety of reboxetine plus citalopram in treatment-resistant depression: an open, naturalistic case series. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology 10-14 December, 2000. San Juan, Puerto Rico: American College of Neuropsychopharmacology, 2000.
60. Fleishaker J. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clinical Pharmacokinetics 2000; 39:413-427.
61. Nolen W, Haffmans P, Bouvy P, Duivenvoorden H. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. Journal of Affective Disorders 1993; 28:189-197.
62. Thase M, Sachs G. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biological Psychiatry 2000; 48:558-572.
63. Parker G, Roy K, Wilhelm K, Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. Journal of Clinical Psychiatry 2001; 62:117-125.
64. Post RM. Mood disorders. In: Kaplan H, Sadock B, eds. Comprehensive textbook of psychiatry, 6th edn. Baltimore: Williams & Wilkins: 1995:1152-1178.
65. Lader M. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. Journal of Clinical Psychiatry 1983; 44:20-24.
66. Fawcett J, Kravitz H, Zajecka J, Schaff M. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. Journal of Clinical Psychopharmacology 1991; 11:127-132.
67. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. American Journal of Geriatric Psychiatry 2001; 9:298-303.
68. Menza M, Kaufman K, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. Journal of Clinical Psychiatry 2000; 61:378-381.
69. Taylor F, Prather M. The efficiency of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder. Depression and Anxiety 2003; 18:83-88.
70. Kornbluh R, Papakostas G, Petersen T et al. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacology Bulletin 2001; 35:150-156.
71. Michalak E, Lam R. Breaking the myths: new treatment approaches for chronic depression. Canadian Journal of Psychiatry 2002; 47:635-643.
72. Kennedy S, Segal Z, Cohen N, Levitan R, Gemar M, Bagby R. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Journal of Clinical Psychiatry 2003; 64:439-444.
73. Perlis R, Nierenberg A, Alpert J et al. Effects of adding cognitive therapy to fluoxetine dose increases risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. Journal of Clinical Psychopharmacology 2002; 22:474-480.